Esketamine alleviates COPD-depression comorbidity in rats via MAPK/NF-κB inhibition and gut-lung-brain axis modulation. J Neuroinflammation January 22, 2026 Esketamine alleviates COPD-depression comorbidity in rats via MAPK/NF-κB inhibition and gut-lung-brain axis modulation. DOI: 10.1186/s12974-026-03699-1 (opens in new tab) Full text (opens in new tab)